Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2017 1
2018 1
2020 1
2021 4
2022 6
2023 6
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.
Castro JT, Brito R, Hojo-Souza NS, Azevedo B, Salazar N, Ferreira CP, Junqueira C, Fernandes AP, Vasconcellos R, Cardoso JM, Aguiar-Soares RDO, Vieira PMA, Carneiro CM, Valiate B, Toledo C, Salazar AM, Caballero O, Lannes-Vieira J, Teixeira SR, Reis AB, Gazzinelli RT. Castro JT, et al. Among authors: hojo souza ns. NPJ Vaccines. 2023 May 31;8(1):81. doi: 10.1038/s41541-023-00676-0. NPJ Vaccines. 2023. PMID: 37258518 Free PMC article.
Second wave of COVID-19 in Brazil: younger at higher risk.
de Souza FSH, Hojo-Souza NS, da Silva CM, Guidoni DL. de Souza FSH, et al. Among authors: hojo souza ns. Eur J Epidemiol. 2021 Apr;36(4):441-443. doi: 10.1007/s10654-021-00750-8. Epub 2021 Apr 21. Eur J Epidemiol. 2021. PMID: 33881666 Free PMC article. No abstract available.
Quality attributes of CTVad1, a nanoemulsified adjuvant for phase I clinical trial of SpiN COVID-19 vaccine.
Dias Assis BR, Gomes IP, de Castro JT, Rivelli GG, de Castro NS, Gomez-Mendoza DP, Bagno FF, Hojo-Souza NS, Chaves Maia AL, Lages EB, da Fonseca FG, Ribeiro Teixeira SM, Fernandes AP, Gazzinelli RT, Castro Goulart GA. Dias Assis BR, et al. Among authors: hojo souza ns. Nanomedicine (Lond). 2023 Aug;18(18):1175-1194. doi: 10.2217/nnm-2023-0122. Epub 2023 Sep 15. Nanomedicine (Lond). 2023. PMID: 37712604 Clinical Trial.
Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
Castro JT, Azevedo P, Fumagalli MJ, Hojo-Souza NS, Salazar N, Almeida GG, Oliveira LI, Faustino L, Antonelli LR, Marçal TG, Augusto M, Valiate B, Fiorini A, Rattis B, Ramos SG, Piccin M, Nonato OC, Benevides L, Magalhães R, Cassaro B, Burle G, Doro D, Kalil J, Durigon E, Salazar A, Caballero O, Santiago H, Machado A, Silva JS, da Fonseca F, Fernandes AP, Teixeira SR, Gazzinelli RT. Castro JT, et al. Among authors: hojo souza ns. Nat Commun. 2022 Aug 17;13(1):4831. doi: 10.1038/s41467-022-32547-y. Nat Commun. 2022. PMID: 35977933 Free PMC article.
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.
Azevedo PO, Hojo-Souza NS, Faustino LP, Fumagalli MJ, Hirako IC, Oliveira ER, Figueiredo MM, Carvalho AF, Doro D, Benevides L, Durigon E, Fonseca F, Machado AM, Fernandes AP, Teixeira SR, Silva JS, Gazzinelli RT. Azevedo PO, et al. Among authors: hojo souza ns. NPJ Vaccines. 2023 Feb 13;8(1):15. doi: 10.1038/s41541-023-00616-y. NPJ Vaccines. 2023. PMID: 36781862 Free PMC article.
22 results